A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

STATUS

Recruiting
End date

Jan 24, 2023
participants needed

474
sponsor

Karyopharm Therapeutics Inc

Send

Updated on 24 April 2022

See if I qualify

platelet count

cancer

corticosteroids

measurable disease

MRI

neutrophil count

blood transfusion

bevacizumab

carmustine

recurrent disease

temozolomide

brain tumor

recurrent glioblastoma

lomustine

renal function test

methylated

ccnu

Summary

This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted in 2 phases: a Phase 1a dose finding study followed by Phase 1b (dose expansion) and a Phase 2 randomized efficacy exploration study and will independently evaluate 3 different combination regimens in 3 treatment arms in patients with nGBM (Arms A and B) or with rGBM (Arm C).

Arm A: evaluating the combination of selinexor with radiation therapy (S-RT) in nGBM participants with uMGMT
Arm B: evaluating the combination of selinexor with radiation therapy and temozolomide (TMZ) (S-TRT) in nGBM participants with methylated-O6-methylguanine-DNA-methyltransferase (mMGMT)
Arm C: evaluating the combination of selinexor with lomustine (or carmustine, if lomustine is not available) (S-L/C) in rGBM participants regardless of MGMT status
Arm D: evaluating the combination of selinexor with bevacizumab in rGBM participants regardless of MGMT status
Arm E: evaluating the combination of selinexor with tumor treating fields (TTField) in rGBM participants regardless of MGMT status

Details

Condition	Glioblastoma Multiforme
Treatment	bevacizumab, carmustine, Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), TTField
Clinical Study Identifier	NCT04421378
Sponsor	Karyopharm Therapeutics Inc
Last Modified on	24 April 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Written informed consent in accordance with federal, local, and institutional guidelines
	Age ≥18 years at the time of informed consent and ≥22 year for Arm E
	Pathologically confirmed glioblastoma (including all histological variants; documentation to be provided) that are newly diagnosed (for Arms A and B) or relapsed disease (for Arm C, D and E) after 1 to 2 line of systemic therapy (RT ± TMZ or RT ± TMZ in combination with other drug) (surgical resection of recurrent disease allowed). For Arms A and B, MGMT status should be available
	Arms A and B: participants who have not received RT or any systemic therapy for brain tumor and must be eligible for definitive external beam RT and TMZ
	Arm C, D and E: participants must have received prior treatment with RT with or without TMZ and only 1 prior line of therapy (RT ± TMZ in combination with other drug is allowed)
	Prior therapy
	Measurable disease according to RANO/modified RANO guidelines is required only for Arm
	Participants enrolling into Arms C, D, and E must be on a stable or decreasing dose of corticosteroids (or none) for at least 5 days prior to the baseline magnetic resonance imaging (MRI)
	C, D and E; it is not required for Arms A or B
	Karnofsky Performance Score (KPS) ≥70 (for Arms A and B) and 60 (for Arms C, D, and E)
	Participants must have adequate organ function ≤2 weeks of study treatment as defined by the following laboratory criteria
	Hematological function ≤7 days prior to Cycle 1 Day 1 (C1 D1): Absolute neutrophil count (ANC) ≥1.5 _10^9 per Liter (/L); platelet count ≥150_ 10^9/L; and hemoglobin (Hb) ≥10.0 gram per deciliter (g/dL). Transfusion is not allowed within 7 days prior to C1 D1
	Hepatic function: bilirubin ≤2 _the upper limit of normal (ULN), alanine transaminase (ALT) ≤2.5_ ULN, aspartate transaminase (AST) ≤2.5 _ULN; unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin must be <4_ULN
	Renal function: calculated (Cockcroft-Gault) or measured creatinine clearance ≥30 milliliter per minute (mL/min)
	Fertile male participants who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 6 months following the last dose of study treatment
	Female participants of childbearing potential must have a negative serum pregnancy
	test at Screening and agree to use highly effective methods of contraception
	throughout the study and for 6 months following the last dose of study
	Limited to supratentorial disease for Arm E only
	treatment
	For Arms A and B: participants must have had surgery and/or biopsy not greater than [>] 8 weeks prior to initial screening
	Participants must consent to provide tumor tissue and blood samples to be used for future molecular testing for correlative studies
Exclusion Criteria
	Participants who are receiving any other investigational agents and /or have had prior therapy including
	For Arms A and B only
	Participants who have previously received RT to the brain
	Participants who received chemotherapy for the treatment of their glioma
	For Arms C, D, and E
	Participants who are being treated with implanted Gliadel wafers
	For Arm C
	Prior nitrosoureas
	<4 weeks from prior TMZ or other chemotherapy, or <4 weeks or 5 half-lives (whichever is shorter) for investigational agents prior to start of study treatment
	Prior treatment bevacizumab or other direct Vascular endothelial growth factor/Vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors. For any questions of the definition of a direct VEGF/VEGFR inhibitor, consult the study Medical Monitor
	Any AE which has not recovered to Grade <=1, or returned to baseline, related to the previous GBM therapy, except alopecia, and some other Grade 2 AEs that have been stabilized (upon Medical Monitor approval)
	History of allergic reactions attributed to compounds of similar chemical or biological composition to selinexor or other study treatment
	Participants must not have significantly diseased or obstructed gastrointestinal tract malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medication
	Participants with mutated isocitrate dehydrogenase (IDH) should be excluded for Phase 2
	Currently pregnant or breastfeeding
	Participants who are being treated or plan to be treated during this study with TTField for participants in Arms A to D
	For Arms A and B: participants with pre-existing known or suspected radiation sensitivity syndromes will be excluded due to potential confounding effect on outcome
	Major surgery <2 weeks prior to the start of study treatment for Arms A to C and E, <4 weeks for Arm D
	Any life-threatening illness, active medical condition, organ system dysfunction, or serious active psychiatric issue which, in the Investigator's opinion, could compromise the participant's safety or the participant's ability to remain compliant with study procedures
	Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable even if parenteral
	Participants with coagulation problems and medically significant bleeding in the month prior to start of treatment (peptic ulcers, epistaxis, intracranial hemorrhage, spontaneous bleeding). Prior history of deep vein thrombosis or pulmonary embolism is not exclusionary
	For participants in Arm C, Forced Vital Capacity (FVC) or Carbon Monoxide Diffusing Capacity (DLCO) below 70% of predicted
	For Arm E: implanted active electronic medical devices such as programmable intraventricular shunts, spinal cord, vagus nerve or deep brain stimulators, pacemakers or implantable automatic defibrillators, skull defect (i.e. missing bone with no replacement), sensitivity to conductive hydrogels as used in electrocardiograms (ECGs), an underlying serious scalp condition that may interfere with placement of arrays, or bullet fragments, or documented clinically significant arrhythmias

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

recurrent glioblastoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma